In an adult with acute bacterial sinusitis who may also have community‑acquired pneumonia, which antibiotic provides coverage for both conditions?

Antibiotic Coverage for Both Sinusitis and Pneumonia

Amoxicillin-clavulanate is the single best antibiotic choice to cover both acute bacterial sinusitis and community-acquired pneumonia in adults, providing broad-spectrum coverage against the overlapping pathogens of both conditions.

Rationale for Amoxicillin-Clavulanate

Amoxicillin-clavulanate (Augmentin) is the preferred first-line agent because it effectively covers the key bacterial pathogens responsible for both conditions 1:

• For sinusitis: Covers Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella catarrhalis 1
• For pneumonia: Provides excellent activity against S. pneumoniae (the most common pneumonia pathogen) and H. influenzae 1, 2
• The clavulanate component overcomes β-lactamase resistance, which is present in nearly 50% of H. influenzae and 90-100% of M. catarrhalis strains 1, 2

Dosing Considerations

For dual coverage, use high-dose amoxicillin-clavulanate:

• Adults: Amoxicillin-clavulanate 2000/125 mg twice daily (pharmacokinetically enhanced formulation) provides optimal coverage for drug-resistant S. pneumoniae while maintaining activity against β-lactamase producers 2, 3
• Standard dosing: Amoxicillin-clavulanate 875/125 mg twice daily is acceptable for uncomplicated cases 1
• Duration: 5-10 days for sinusitis 1 and minimum 5 days for pneumonia 1

Alternative Options Based on Clinical Context

Respiratory Fluoroquinolones (Second-Line)

If the patient has penicillin allergy or recent β-lactam exposure, respiratory fluoroquinolones provide excellent dual coverage 1:

• Levofloxacin 750 mg daily or moxifloxacin 400 mg daily cover both typical and atypical pathogens for both conditions 1
• These agents have enhanced activity against S. pneumoniae (including resistant strains), H. influenzae, M. catarrhalis, and atypical organisms (Mycoplasma, Chlamydophila, Legionella) 1, 4, 5
• Caution: Reserve fluoroquinolones for patients with comorbidities or antibiotic allergies due to concerns about resistance selection and adverse effects (tendinopathy, cardiac arrhythmias) 1

Combination Therapy for Hospitalized Patients

For hospitalized patients with more severe pneumonia, combination therapy is preferred 1:

• β-lactam (ceftriaxone 1-2 g daily or cefotaxime 1-2 g every 8 hours) PLUS macrolide (azithromycin 500 mg daily) provides optimal coverage 1, 6
• This combination covers both sinusitis and pneumonia pathogens while adding atypical coverage 1
• Minimum duration: 3 days for hospitalized pneumonia patients who are clinically stable 1, 6

Pathogens Not Adequately Covered

Important caveats to avoid treatment failure:

• Ciprofloxacin should NOT be used as it has inadequate activity against S. pneumoniae (the primary pathogen in both conditions) 1
• First-generation cephalosporins (cephalexin, cefadroxil) have poor coverage for H. influenzae and should be avoided 1
• Macrolide monotherapy is increasingly unreliable due to rising pneumococcal resistance rates 1

Clinical Decision Algorithm

Choose antibiotic based on severity and setting:

1. Outpatient, uncomplicated, no recent antibiotics: Amoxicillin-clavulanate 875/125 mg twice daily 1
2. Outpatient with comorbidities or recent β-lactam use: Respiratory fluoroquinolone (levofloxacin 750 mg or moxifloxacin 400 mg daily) 1
3. Hospitalized (non-ICU): Ceftriaxone 1-2 g daily PLUS azithromycin 500 mg daily 1, 6
4. Penicillin allergy: Respiratory fluoroquinolone monotherapy OR doxycycline 100 mg twice daily (though doxycycline has limited pneumococcal coverage) 1

This approach ensures coverage of the overlapping pathogen spectrum while minimizing resistance selection and adverse effects.